On 8 March 2018, the UK Competition Appeal Tribunal referred specific questions on the so-called “pay-for-delay agreements” to the Court of Justice of the European Union (CJEU) in the case of GSK and generic drug manufacturers against the Competition and Markets Authority (CMA) . In February 2016, the CMA determined that GSK and five other companies had concluded anti-competitive agreements and imposed significant penalties on those companies. The infringements were the result of agreements concerning the anti-depressant drug, paroxetine (Seroxat). According to the CMA, GSK had entered into agreements with the generic drug manufacturers whereby GSK had paid these companies to delay the market entry of an independent generic drug and to drop patent challenges against GSK. According to the UK Competition Appeal Tribunal, these “pay-for-delay” agreements , in all the circumstances, give rise to infringements of competition law. The Tribunal is now asking for guidance from the CJEU on how to interpret the object and effect of the agreements in the light of Article 101 TFEU.